Intended for healthcare professionals

Latest dermatology news

 

Amgen/Kyowa Kirin’s rocatinlimab shows promise in phase 3 atopic dermatitis trial

Up to 20% of children and 10% of adults globally are affected by the skin disease

27 Mar 2025

J&J/Protagonist share positive phase 3 results for icotrokinra in plaque psoriasis

The immune-mediated skin disease impacts over 125 million people worldwide

27 Mar 2025

EC approves Biocon’ Yesintek to treat psoriasis

The Stelara biosimilar has been authorised to treat plaque psoriasis and psoriatic arthritis

20 Mar 2025

BMS announces long-term data for Sotyktu in plaque psoriasis

At least 100 million people worldwide are affected by some form of psoriasis

20 Mar 2025

EMA committee recommends Krystal’s Vyjuvek for ultra-rare blistering disease

There is currently only one treatment authorised for dystrophic epidermolysis bullosa

19 Mar 2025

MHRA approves Galderma’s Nemluvio for two skin diseases

The drug has been approved to treat both atopic dermatitis and prurigo nodularis

19 Mar 2025

Recce shares positive mid-stage results for topical gel in skin infections

The company said the data confirms the approach for its approved phase 3 diabetic foot infections study

06 Mar 2025

Sanofi/Regeneron’s Dupixent receives FDA priority review for bullous pemphigoid

If approved, Dupixent would be the first and only targeted medicine to treat BP in the US

06 Mar 2025

Key milestone for Biofrontera’s phase 3 skin cancer trial

Approximately 3.6 million cases of basal cell carcinoma are diagnosed in the US every year

27 Feb 2025

FDA gives Alys Pharmaceuticals IND clearance for alopecia areata trial

Approximately 700,000 people in the US currently have some form of alopecia areata

20 Feb 2025
12345678910...